Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.71 |
| ▸ | STAT3 | P40763 | 2/20 | 0.54 |
| ▸ | GRAMD1A | Q96CP6 | 4/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071074 | 0.93 | CRBN (0.70) | CRBNDDB1STAT3GRAMD1ACA2 | |
| SCHEMBL21070292 | 0.93 | CRBN (0.69) | CRBNDDB1STAT3GRAMD1ACA2 | |
| SCHEMBL21069587 | 0.93 | CRBN (0.69) | CRBNDDB1STAT3GRAMD1ACA2 | |
| SCHEMBL30288355 | 0.89 | CRBN (0.70) | CRBNDDB1STAT3GRAMD1AHDAC8 | |
| SCHEMBL26812783 | 0.89 | CRBN (0.70) | CRBNDDB1STAT3GRAMD1AHDAC8 | |
| SCHEMBL23575837 | 0.89 | DDB1 (0.67) | CRBNDDB1STAT3GRAMD1A | |
| SCHEMBL23884304 | 0.89 | CRBN (0.56) | CRBNDDB1STAT3CA2 | |
| SCHEMBL23884126 | 0.89 | CRBN (0.56) | CRBNDDB1STAT3CA2 | |
| SCHEMBL23884307 | 0.89 | CRBN (0.56) | CRBNDDB1STAT3CA2 | |
| SCHEMBL26828213 | 0.88 | CRBN (0.71) | CRBNDDB1STAT3GRAMD1ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885STAT3 4250/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885STAT3 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.